This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.

Investment Insights - Stanley Druckenmiller, a highly successful investor, is investing in Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceutical (NYSE:TEVA) [1] - Druckenmiller has a long history of high returns in global macro investing, producing average annual returns of around 30% with no losing years at Duquesne Capital Management from 1981 to 2010 [5][8] Natera (NTRA) - Natera is a genetic testing company specializing in cell-free DNA (cfDNA) for diagnostic tests, including non-invasive prenatal tests [6] - NTRA stock has increased over 500% since its low in October 2023, with revenue rising 34.66% year-over-year in Q3 2025, beating analyst estimates by 13.9% [7] - Management has raised full-year revenue guidance to between $2.18 billion and $2.26 billion, following a previous increase in Q2 2025 [7] Insmed (INSM) - Insmed's stock price surged from below $26 in May 2024 to nearly $200, with revenue growing 52% year-over-year in Q3 2025 [8]